EGFR and non-small cell lung carcinoma: This is in accordance with the latest guidelines published in 2018, which strongly recommended, during the diagnosis of advanced or metastatic NSCLC, in addition to PD-L1, the search for EGFR mutations and rearrangements involving genes such as ALK and ROS1 and also encouraged screening for other alterations such as BRAF, HER2, MET, RET, and NTRK [14].